losartan has been researched along with exp-3179 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Aldrich, PE; Carini, DJ; Chiu, AT; Duncia, JV; Johnson, AL; Pierce, ME; Price, WA; Santella, JB; Wells, GJ; Wexler, RR | 1 |
| Fukami, T; Hosomi, H; Iwamura, A; Nakajima, M; Yokoi, T | 1 |
| Foster, H; Foster, R; Philippou, H; Wilson, C | 1 |
3 other study(ies) available for losartan and exp-3179
| Article | Year |
|---|---|
Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives.
Topics: Administration, Oral; Adrenal Glands; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Chemical Phenomena; Chemistry; Hypertension; Imidazoles; Losartan; Male; Molecular Structure; Rats; Rats, Inbred Strains; Receptors, Angiotensin; Structure-Activity Relationship; Tetrazoles | 1991 |
CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
Topics: Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Benzbromarone; Biotransformation; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C9; Diclofenac; HEK293 Cells; Hep G2 Cells; Hepatocytes; Humans; Losartan; NF-E2-Related Factor 2; Semicarbazides; Sensitivity and Specificity; Time Factors; Uricosuric Agents | 2011 |
Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
Topics: Binding Sites; Biological Products; Humans; Ligands; Losartan; Molecular Dynamics Simulation; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Protein Kinase Inhibitors; Signal Transduction; Small Molecule Libraries; Thrombosis | 2020 |